EU External Trade - PHARMACEUTICAL PRODUCTS, Glands and other organs for organo-therapeutic uses, dried, whether or not powdered; extracts of glands or other organs or of their secretions for organo-therapeutic uses; heparin and its salts; other human or animal substances prepared for therapeutic or prophylactic uses, not elsewhere specified or included

Extra-EU sourcing of PHARMACEUTICAL PRODUCTS, Glands and other organs for organo-therapeutic uses, dried, whether or not powdered; extracts of glands or other organs or of their secretions for organo-therapeutic uses; heparin and its salts; other human or animal substances prepared for therapeutic or prophylactic uses, not elsewhere specified or included is highly concentrated. 🇸🇬 Singapore captures 39.9% of imports (€1.8B), followed by 🇺🇸 United States (26.0%). With an HHI of 2942, this Concentrated market exposes the EU to supply dependency risks.

European exports of PHARMACEUTICAL PRODUCTS, Glands and other organs for organo-therapeutic uses, dried, whether or not powdered; extracts of glands or other organs or of their secretions for organo-therapeutic uses; heparin and its salts; other human or animal substances prepared for therapeutic or prophylactic uses, not elsewhere specified or included are concentrated on a few markets. 🇸🇬 Singapore accounts for 59.6% (€1.6B), ahead of 🇺🇸 United States (8.1%). The top three destinations are 🇸🇬 Singapore, 🇺🇸 United States, 🇨🇳 China.

Within the EU, the leading importers of PHARMACEUTICAL PRODUCTS, Glands and other organs for organo-therapeutic uses, dried, whether or not powdered; extracts of glands or other organs or of their secretions for organo-therapeutic uses; heparin and its salts; other human or animal substances prepared for therapeutic or prophylactic uses, not elsewhere specified or included are 🇫🇷 France, 🇭🇺 Hungary, 🇪🇸 Spain. 🇫🇷 France accounts for 26.4% of EU imports.

In 2025, imports were falling sharply (-27.2%) and exports declining (-9.2%) compared to the previous year.